Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36006442)

  • 1. HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study.
    Wang M; Wang X; Li Y; Li Q; Cai S; Li X; Ma M
    Int J Colorectal Dis; 2022 Sep; 37(9):2061-2067. PubMed ID: 36006442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
    Zong L; Chen P; Wang DX
    World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
    Feng Y; Li Y; Huang D; Cai S; Peng J
    Eur J Surg Oncol; 2019 Feb; 45(2):167-173. PubMed ID: 30420187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
    Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
    Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of peripheral nerve invasion with clinicopathological factors and prognosis of colorectal cancer].
    Han D; Wei Y; Wang X; Wang G; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):62-66. PubMed ID: 28105622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
    Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
    BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
    Liu F; Ren C; Jin Y; Xi S; He C; Wang F; Wang Z; Xu RH; Wang F
    Virchows Arch; 2020 Mar; 476(3):391-398. PubMed ID: 31720832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
    Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
    Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O; Duman BB; Kara B; Erdogan S; Parsak CK; Sakman G
    Asian Pac J Cancer Prev; 2012; 13(12):6397-401. PubMed ID: 23464465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
    Shan L; Lv Y; Bai B; Huang X; Zhu H
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2275-2281. PubMed ID: 30203148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
    Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu testing in primary colorectal carcinoma.
    Ingold Heppner B; Behrens HM; Balschun K; Haag J; Krüger S; Becker T; Röcken C
    Br J Cancer; 2014 Nov; 111(10):1977-84. PubMed ID: 25211663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study.
    Cao Y; Deng S; Yan L; Gu J; Li J; Wu K; Cai K
    Int J Colorectal Dis; 2020 Jun; 35(6):1067-1075. PubMed ID: 32179991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
    Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
    World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
    Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
    Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer.
    Wu Z; Cheng Y; Wang H; Liu D; Qi X; Wang C; Zhang Y; Zhang Y; Cai R; Huo H; Zhang J; Cai Y; Li W; Hu H; Deng Y
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.